ARS Pharmaceuticals, Inc. (SPRY) Reports In-Line Q2 EPS

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q2 EPS of ($0.46), in-line with the analyst estimate of ($0.46). Revenue for the quarter came in at $15.72 million versus the consensus estimate of $13.77 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance
• Canadian Solar unit wins 426 MWh battery storage deal in Florida
• BofA Securities Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral